Lipid Nanoparticles: Key Facilitators of mRNA Vaccine Development
The current applications of nanomedicine span from the treatment of an infection right up to the treatment of cancer. Lipid nanoparticles (LNPs) have established themselves as reliable delivery systems for delivering therapeutic agents including nucleic acids since they prevent in vivo degradation o...
Gespeichert in:
| Veröffentlicht in: | Biosciences, biotechnology research Asia biotechnology research Asia, 2022-03, Vol.19 (1), p.199-213 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 213 |
|---|---|
| container_issue | 1 |
| container_start_page | 199 |
| container_title | Biosciences, biotechnology research Asia |
| container_volume | 19 |
| creator | Cholkar, Shalmali Shirish Gawade, Ashwini Ramkrishana Kuchekar, Ashwin Bhanudas |
| description | The current applications of nanomedicine span from the treatment of an infection right up to the treatment of cancer. Lipid nanoparticles (LNPs) have established themselves as reliable delivery systems for delivering therapeutic agents including nucleic acids since they prevent in vivo degradation of nucleic acids and facilitate their target-specific delivery. The mRNA is one such nucleic acid that is delivered by the LNPs for the treatment of infectious diseases. This review provides a detailed insight into the concept of messenger RNA (mRNA) vaccines, their mechanism of action, manufacturing process, critical considerations in the formulation, development, and manufacturing of these vaccines, and explains the vital role of LNPs in the development of these vaccines. Certain shortcomings of the lipid nanoparticle-mRNA vaccine concerning the in vitro stability of the mRNA and the LNP have also been highlighted in this review. |
| doi_str_mv | 10.13005/bbra/2979 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2649749692</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2649749692</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1409-6474721cfce50a931d3fbb9b9fde31b3c14b76e16d393bb52689d02196d19e823</originalsourceid><addsrcrecordid>eNotkMFKAzEURYMoWGo3fkHAnTD2JZlJ-tyValUsFUTdhiSTgZTpZEymQv_e1rq6cDncC4eQawZ3TABUU2uTmXJUeEZGvKxkwSXwczICVKJgh-aSTHLeAAAHBMXYiMxXoQ81XZsu9iYNwbU-39NXv6dL40IbBjPElGls6PZ9PadfxrnQefrgf3wb-63vhity0Zg2-8l_jsnn8vFj8Vys3p5eFvNV4VgJWMhSlYoz1zhfgUHBatFYixab2gtmxYGySnoma4HC2orLGdbAGcqaoZ9xMSY3p90-xe-dz4PexF3qDpeayxJViRKP1O2JcinmnHyj-xS2Ju01A_1nSR8t6aMl8QsQr1ic</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2649749692</pqid></control><display><type>article</type><title>Lipid Nanoparticles: Key Facilitators of mRNA Vaccine Development</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Cholkar, Shalmali Shirish ; Gawade, Ashwini Ramkrishana ; Kuchekar, Ashwin Bhanudas</creator><creatorcontrib>Cholkar, Shalmali Shirish ; Gawade, Ashwini Ramkrishana ; Kuchekar, Ashwin Bhanudas</creatorcontrib><description>The current applications of nanomedicine span from the treatment of an infection right up to the treatment of cancer. Lipid nanoparticles (LNPs) have established themselves as reliable delivery systems for delivering therapeutic agents including nucleic acids since they prevent in vivo degradation of nucleic acids and facilitate their target-specific delivery. The mRNA is one such nucleic acid that is delivered by the LNPs for the treatment of infectious diseases. This review provides a detailed insight into the concept of messenger RNA (mRNA) vaccines, their mechanism of action, manufacturing process, critical considerations in the formulation, development, and manufacturing of these vaccines, and explains the vital role of LNPs in the development of these vaccines. Certain shortcomings of the lipid nanoparticle-mRNA vaccine concerning the in vitro stability of the mRNA and the LNP have also been highlighted in this review.</description><identifier>ISSN: 0973-1245</identifier><identifier>EISSN: 2456-2602</identifier><identifier>DOI: 10.13005/bbra/2979</identifier><language>eng</language><publisher>Bhopal: Biosciences Biotechnology Research Asia</publisher><subject>Acids ; Alzheimer's disease ; Antigens ; Chemical compounds ; Chronic obstructive pulmonary disease ; Coronaviruses ; COVID-19 ; Cytoplasm ; Dendritic cells ; Enzymes ; Genetic engineering ; Genomes ; Immune system ; Infectious diseases ; Lipids ; Manufacturing ; mRNA stability ; mRNA vaccines ; Nanoparticles ; Nanotechnology ; Nucleic acids ; Pandemics ; Parkinson's disease ; Pharmacology ; Proteins ; RNA polymerase ; Tuberculosis ; Vaccine development ; Vaccines</subject><ispartof>Biosciences, biotechnology research Asia, 2022-03, Vol.19 (1), p.199-213</ispartof><rights>2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1409-6474721cfce50a931d3fbb9b9fde31b3c14b76e16d393bb52689d02196d19e823</citedby><cites>FETCH-LOGICAL-c1409-6474721cfce50a931d3fbb9b9fde31b3c14b76e16d393bb52689d02196d19e823</cites><orcidid>0000-0001-7768-9481 ; 0000-0003-0496-6059 ; 0000-0003-4171-0319</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Cholkar, Shalmali Shirish</creatorcontrib><creatorcontrib>Gawade, Ashwini Ramkrishana</creatorcontrib><creatorcontrib>Kuchekar, Ashwin Bhanudas</creatorcontrib><title>Lipid Nanoparticles: Key Facilitators of mRNA Vaccine Development</title><title>Biosciences, biotechnology research Asia</title><description>The current applications of nanomedicine span from the treatment of an infection right up to the treatment of cancer. Lipid nanoparticles (LNPs) have established themselves as reliable delivery systems for delivering therapeutic agents including nucleic acids since they prevent in vivo degradation of nucleic acids and facilitate their target-specific delivery. The mRNA is one such nucleic acid that is delivered by the LNPs for the treatment of infectious diseases. This review provides a detailed insight into the concept of messenger RNA (mRNA) vaccines, their mechanism of action, manufacturing process, critical considerations in the formulation, development, and manufacturing of these vaccines, and explains the vital role of LNPs in the development of these vaccines. Certain shortcomings of the lipid nanoparticle-mRNA vaccine concerning the in vitro stability of the mRNA and the LNP have also been highlighted in this review.</description><subject>Acids</subject><subject>Alzheimer's disease</subject><subject>Antigens</subject><subject>Chemical compounds</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Cytoplasm</subject><subject>Dendritic cells</subject><subject>Enzymes</subject><subject>Genetic engineering</subject><subject>Genomes</subject><subject>Immune system</subject><subject>Infectious diseases</subject><subject>Lipids</subject><subject>Manufacturing</subject><subject>mRNA stability</subject><subject>mRNA vaccines</subject><subject>Nanoparticles</subject><subject>Nanotechnology</subject><subject>Nucleic acids</subject><subject>Pandemics</subject><subject>Parkinson's disease</subject><subject>Pharmacology</subject><subject>Proteins</subject><subject>RNA polymerase</subject><subject>Tuberculosis</subject><subject>Vaccine development</subject><subject>Vaccines</subject><issn>0973-1245</issn><issn>2456-2602</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNotkMFKAzEURYMoWGo3fkHAnTD2JZlJ-tyValUsFUTdhiSTgZTpZEymQv_e1rq6cDncC4eQawZ3TABUU2uTmXJUeEZGvKxkwSXwczICVKJgh-aSTHLeAAAHBMXYiMxXoQ81XZsu9iYNwbU-39NXv6dL40IbBjPElGls6PZ9PadfxrnQefrgf3wb-63vhity0Zg2-8l_jsnn8vFj8Vys3p5eFvNV4VgJWMhSlYoz1zhfgUHBatFYixab2gtmxYGySnoma4HC2orLGdbAGcqaoZ9xMSY3p90-xe-dz4PexF3qDpeayxJViRKP1O2JcinmnHyj-xS2Ju01A_1nSR8t6aMl8QsQr1ic</recordid><startdate>20220331</startdate><enddate>20220331</enddate><creator>Cholkar, Shalmali Shirish</creator><creator>Gawade, Ashwini Ramkrishana</creator><creator>Kuchekar, Ashwin Bhanudas</creator><general>Biosciences Biotechnology Research Asia</general><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0001-7768-9481</orcidid><orcidid>https://orcid.org/0000-0003-0496-6059</orcidid><orcidid>https://orcid.org/0000-0003-4171-0319</orcidid></search><sort><creationdate>20220331</creationdate><title>Lipid Nanoparticles: Key Facilitators of mRNA Vaccine Development</title><author>Cholkar, Shalmali Shirish ; Gawade, Ashwini Ramkrishana ; Kuchekar, Ashwin Bhanudas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1409-6474721cfce50a931d3fbb9b9fde31b3c14b76e16d393bb52689d02196d19e823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acids</topic><topic>Alzheimer's disease</topic><topic>Antigens</topic><topic>Chemical compounds</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Cytoplasm</topic><topic>Dendritic cells</topic><topic>Enzymes</topic><topic>Genetic engineering</topic><topic>Genomes</topic><topic>Immune system</topic><topic>Infectious diseases</topic><topic>Lipids</topic><topic>Manufacturing</topic><topic>mRNA stability</topic><topic>mRNA vaccines</topic><topic>Nanoparticles</topic><topic>Nanotechnology</topic><topic>Nucleic acids</topic><topic>Pandemics</topic><topic>Parkinson's disease</topic><topic>Pharmacology</topic><topic>Proteins</topic><topic>RNA polymerase</topic><topic>Tuberculosis</topic><topic>Vaccine development</topic><topic>Vaccines</topic><toplevel>online_resources</toplevel><creatorcontrib>Cholkar, Shalmali Shirish</creatorcontrib><creatorcontrib>Gawade, Ashwini Ramkrishana</creatorcontrib><creatorcontrib>Kuchekar, Ashwin Bhanudas</creatorcontrib><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Biosciences, biotechnology research Asia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cholkar, Shalmali Shirish</au><au>Gawade, Ashwini Ramkrishana</au><au>Kuchekar, Ashwin Bhanudas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipid Nanoparticles: Key Facilitators of mRNA Vaccine Development</atitle><jtitle>Biosciences, biotechnology research Asia</jtitle><date>2022-03-31</date><risdate>2022</risdate><volume>19</volume><issue>1</issue><spage>199</spage><epage>213</epage><pages>199-213</pages><issn>0973-1245</issn><eissn>2456-2602</eissn><abstract>The current applications of nanomedicine span from the treatment of an infection right up to the treatment of cancer. Lipid nanoparticles (LNPs) have established themselves as reliable delivery systems for delivering therapeutic agents including nucleic acids since they prevent in vivo degradation of nucleic acids and facilitate their target-specific delivery. The mRNA is one such nucleic acid that is delivered by the LNPs for the treatment of infectious diseases. This review provides a detailed insight into the concept of messenger RNA (mRNA) vaccines, their mechanism of action, manufacturing process, critical considerations in the formulation, development, and manufacturing of these vaccines, and explains the vital role of LNPs in the development of these vaccines. Certain shortcomings of the lipid nanoparticle-mRNA vaccine concerning the in vitro stability of the mRNA and the LNP have also been highlighted in this review.</abstract><cop>Bhopal</cop><pub>Biosciences Biotechnology Research Asia</pub><doi>10.13005/bbra/2979</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-7768-9481</orcidid><orcidid>https://orcid.org/0000-0003-0496-6059</orcidid><orcidid>https://orcid.org/0000-0003-4171-0319</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0973-1245 |
| ispartof | Biosciences, biotechnology research Asia, 2022-03, Vol.19 (1), p.199-213 |
| issn | 0973-1245 2456-2602 |
| language | eng |
| recordid | cdi_proquest_journals_2649749692 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | Acids Alzheimer's disease Antigens Chemical compounds Chronic obstructive pulmonary disease Coronaviruses COVID-19 Cytoplasm Dendritic cells Enzymes Genetic engineering Genomes Immune system Infectious diseases Lipids Manufacturing mRNA stability mRNA vaccines Nanoparticles Nanotechnology Nucleic acids Pandemics Parkinson's disease Pharmacology Proteins RNA polymerase Tuberculosis Vaccine development Vaccines |
| title | Lipid Nanoparticles: Key Facilitators of mRNA Vaccine Development |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A44%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipid%20Nanoparticles:%20Key%20Facilitators%20of%20mRNA%20Vaccine%20Development&rft.jtitle=Biosciences,%20biotechnology%20research%20Asia&rft.au=Cholkar,%20Shalmali%20Shirish&rft.date=2022-03-31&rft.volume=19&rft.issue=1&rft.spage=199&rft.epage=213&rft.pages=199-213&rft.issn=0973-1245&rft.eissn=2456-2602&rft_id=info:doi/10.13005/bbra/2979&rft_dat=%3Cproquest_cross%3E2649749692%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2649749692&rft_id=info:pmid/&rfr_iscdi=true |